Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Mapping the impact of exposure to maternal immune activation on juvenile Wistar rat brain macro- and microstructure during early post-natal development.

Wood TC, Edye ME, Harte MK, Neill JC, Prinssen EP, Vernon AC.

Brain Neurosci Adv. 2019 Jan 1;3:2398212819883086. doi: 10.1177/2398212819883086. Epub 2019 Nov 4.

2.

Poly(I:C) source, molecular weight and endotoxin contamination affect dam and prenatal outcomes, implications for models of maternal immune activation.

Kowash HM, Potter HG, Edye ME, Prinssen EP, Bandinelli S, Neill JC, Hager R, Glazier JD.

Brain Behav Immun. 2019 Nov;82:160-166. doi: 10.1016/j.bbi.2019.08.006. Epub 2019 Aug 12.

PMID:
31415868
3.

Evolution of a maternal immune activation (mIA) model in rats: Early developmental effects.

Murray KN, Edye ME, Manca M, Vernon AC, Oladipo JM, Fasolino V, Harte MK, Mason V, Grayson B, McHugh PC, Knuesel I, Prinssen EP, Hager R, Neill JC.

Brain Behav Immun. 2019 Jan;75:48-59. doi: 10.1016/j.bbi.2018.09.005. Epub 2018 Sep 12.

PMID:
30218784
4.

Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer's Disease.

Borroni E, Bohrmann B, Grueninger F, Prinssen E, Nave S, Loetscher H, Chinta SJ, Rajagopalan S, Rane A, Siddiqui A, Ellenbroek B, Messer J, Pähler A, Andersen JK, Wyler R, Cesura AM.

J Pharmacol Exp Ther. 2017 Sep;362(3):413-423. doi: 10.1124/jpet.117.241653. Epub 2017 Jun 22.

PMID:
28642233
5.

The great barrier belief: The blood-brain barrier and considerations for juvenile toxicity studies.

Schmitt G, Parrott N, Prinssen E, Barrow P.

Reprod Toxicol. 2017 Sep;72:129-135. doi: 10.1016/j.reprotox.2017.06.043. Epub 2017 Jun 13. Review.

PMID:
28627392
6.

Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets.

Bespalov A, Steckler T, Altevogt B, Koustova E, Skolnick P, Deaver D, Millan MJ, Bastlund JF, Doller D, Witkin J, Moser P, O'Donnell P, Ebert U, Geyer MA, Prinssen E, Ballard T, Macleod M.

Nat Rev Drug Discov. 2016 Jul;15(7):516. doi: 10.1038/nrd.2016.88. Epub 2016 Jun 17. No abstract available.

PMID:
27312728
7.

Zebrafish behavioral profiling identifies multitarget antipsychotic-like compounds.

Bruni G, Rennekamp AJ, Velenich A, McCarroll M, Gendelev L, Fertsch E, Taylor J, Lakhani P, Lensen D, Evron T, Lorello PJ, Huang XP, Kolczewski S, Carey G, Caldarone BJ, Prinssen E, Roth BL, Keiser MJ, Peterson RT, Kokel D.

Nat Chem Biol. 2016 Jul;12(7):559-66. doi: 10.1038/nchembio.2097. Epub 2016 May 30.

8.

Characterization of the Discriminative Stimulus Effects of a NOP Receptor Agonist Ro 64-6198 in Rhesus Monkeys.

Saccone PA, Zelenock KA, Lindsey AM, Sulima A, Rice KC, Prinssen EP, Wichmann J, Woods JH.

J Pharmacol Exp Ther. 2016 Apr;357(1):17-23. doi: 10.1124/jpet.115.231134. Epub 2016 Jan 22.

9.

"Domain gauges": A reference system for multivariate profiling of brain fMRI activation patterns induced by psychoactive drugs in rats.

Bruns A, Mueggler T, Künnecke B, Risterucci C, Prinssen EP, Wettstein JG, von Kienlin M.

Neuroimage. 2015 May 15;112:70-85. doi: 10.1016/j.neuroimage.2015.02.032. Epub 2015 Feb 25.

PMID:
25724758
10.

Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression.

Lindemann L, Porter RH, Scharf SH, Kuennecke B, Bruns A, von Kienlin M, Harrison AC, Paehler A, Funk C, Gloge A, Schneider M, Parrott NJ, Polonchuk L, Niederhauser U, Morairty SR, Kilduff TS, Vieira E, Kolczewski S, Wichmann J, Hartung T, Honer M, Borroni E, Moreau JL, Prinssen E, Spooren W, Wettstein JG, Jaeschke G.

J Pharmacol Exp Ther. 2015 Apr;353(1):213-33. doi: 10.1124/jpet.114.222463. Epub 2015 Feb 9.

PMID:
25665805
11.

Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseases.

Jaeschke G, Kolczewski S, Spooren W, Vieira E, Bitter-Stoll N, Boissin P, Borroni E, Büttelmann B, Ceccarelli S, Clemann N, David B, Funk C, Guba W, Harrison A, Hartung T, Honer M, Huwyler J, Kuratli M, Niederhauser U, Pähler A, Peters JU, Petersen A, Prinssen E, Ricci A, Rueher D, Rueher M, Schneider M, Spurr P, Stoll T, Tännler D, Wichmann J, Porter RH, Wettstein JG, Lindemann L.

J Med Chem. 2015 Feb 12;58(3):1358-71. doi: 10.1021/jm501642c. Epub 2015 Feb 2.

PMID:
25565255
12.

Can 5-HT3 antagonists contribute toward the treatment of schizophrenia?

Ellenbroek BA, Prinssen EP.

Behav Pharmacol. 2015 Feb;26(1-2):33-44. doi: 10.1097/FBP.0000000000000102. Review.

PMID:
25356732
13.

Maternal immune activation and abnormal brain development across CNS disorders.

Knuesel I, Chicha L, Britschgi M, Schobel SA, Bodmer M, Hellings JA, Toovey S, Prinssen EP.

Nat Rev Neurol. 2014 Nov;10(11):643-60. doi: 10.1038/nrneurol.2014.187. Epub 2014 Oct 14. Review.

PMID:
25311587
14.

Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review.

Toovey S, Prinssen EP, Rayner CR, Thakrar BT, Dutkowski R, Koerner A, Chu T, Sirzen-Zelenskaya A, Britschgi M, Bansod S, Donner B.

Adv Ther. 2012 Oct;29(10):826-48. doi: 10.1007/s12325-012-0050-8. Epub 2012 Oct 2. Review.

PMID:
23054689
15.

The nociceptin orphanin FQ peptide receptor agonist, Ro64-6198, impairs recognition memory formation through interaction with glutamatergic but not cholinergic receptor antagonists.

Reiss D, Prinssen EP, Wichmann J, Kieffer BL, Ouagazzal AM.

Neurobiol Learn Mem. 2012 Oct;98(3):254-60. doi: 10.1016/j.nlm.2012.09.002. Epub 2012 Sep 13.

PMID:
22982481
16.

Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies.

Poirier A, Belli S, Funk C, Otteneder MB, Portmann R, Heinig K, Prinssen E, Lazic SE, Rayner CR, Hoffmann G, Singer T, Smith DE, Schuler F.

Drug Metab Dispos. 2012 Aug;40(8):1556-65. doi: 10.1124/dmd.112.044990. Epub 2012 May 14.

17.

Absence of central nervous system and hypothermic effects after single oral administration of high doses of oseltamivir in the rat.

Freichel C, Breidenbach A, Hoffmann G, Körner A, Gatti S, Donner B, Bansod S, Bellot M, Gand L, Weiser T, Singer T, Prinssen EP.

Basic Clin Pharmacol Toxicol. 2012 Jul;111(1):50-7. doi: 10.1111/j.1742-7843.2012.00861.x. Epub 2012 Mar 8.

18.

Further characterization of the prototypical nociceptin/orphanin FQ peptide receptor agonist Ro 64-6198 in rodent models of conflict anxiety and despair.

Goeldner C, Spooren W, Wichmann J, Prinssen EP.

Psychopharmacology (Berl). 2012 Jul;222(2):203-14. doi: 10.1007/s00213-012-2636-x. Epub 2012 Jan 18.

PMID:
22249359
19.

Imaging trait anxiety in high anxiety F344 rats: Focus on the dorsomedial prefrontal cortex.

Prinssen EP, Nicolas LB, Klein S, Grundschober C, Lopez-Lopez C, Kessler MS, Bruns A, von Kienlin M, Wettstein JG, Moreau JL, Risterucci C.

Eur Neuropsychopharmacol. 2012 Jun;22(6):441-51. doi: 10.1016/j.euroneuro.2011.11.001. Epub 2011 Dec 6.

PMID:
22153786
20.

Lack of unwanted effects of oseltamivir carboxylate in juvenile rats after subcutaneous administration.

Freichel C, Breidenbach A, Gand L, Toot J, Weiser T, Körner A, Singer T, Prinssen E, Hoffmann G.

Basic Clin Pharmacol Toxicol. 2012 Jun;110(6):551-3. doi: 10.1111/j.1742-7843.2011.00840.x. Epub 2011 Dec 29. No abstract available.

21.

Activation of nociceptin/orphanin FQ peptide receptors disrupts visual but not auditory sensorimotor gating in BALB/cByJ mice: comparison to dopamine receptor agonists.

Ces A, Reiss D, Walter O, Wichmann J, Prinssen EP, Kieffer BL, Ouagazzal AM.

Neuropsychopharmacology. 2012 Jan;37(2):378-89. doi: 10.1038/npp.2011.175. Epub 2011 Aug 31.

22.

PEGylation enhances the therapeutic potential for insulin-like growth factor I in central nervous system disorders.

Saenger S, Goeldner C, Frey JR, Ozmen L, Ostrowitzki S, Spooren W, Ballard TM, Prinssen E, Borroni E, Metzger F.

Growth Horm IGF Res. 2011 Oct;21(5):292-303. doi: 10.1016/j.ghir.2011.07.006. Epub 2011 Aug 23.

PMID:
21865068
23.

CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor.

Lindemann L, Jaeschke G, Michalon A, Vieira E, Honer M, Spooren W, Porter R, Hartung T, Kolczewski S, Büttelmann B, Flament C, Diener C, Fischer C, Gatti S, Prinssen EP, Parrott N, Hoffmann G, Wettstein JG.

J Pharmacol Exp Ther. 2011 Nov;339(2):474-86. doi: 10.1124/jpet.111.185660. Epub 2011 Aug 17.

PMID:
21849627
24.

Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants.

Parrott N, Davies B, Hoffmann G, Koerner A, Lave T, Prinssen E, Theogaraj E, Singer T.

Clin Pharmacokinet. 2011 Sep;50(9):613-23. doi: 10.2165/11592640-000000000-00000.

PMID:
21827216
25.

Absence of adverse effects of oseltamivir on sleep: a double-blind, randomized study in healthy volunteers in Japan.

Uchimura N, Kuwahara H, Kumagai Y, Mishima K, Inoue Y, Rayner CR, Toovey S, Davies BE, Hosaka Y, Abe M, Prinssen EP.

Basic Clin Pharmacol Toxicol. 2011 Oct;109(4):309-14. doi: 10.1111/j.1742-7843.2011.00726.x. Epub 2011 Jun 29.

26.
27.

Functional heterogeneity of nociceptin/orphanin FQ receptors revealed by (+)-5a Compound and Ro 64-6198 in rat periaqueductal grey slices.

Liao YY, Teng SF, Lin LC, Kolczewski S, Prinssen EP, Lee LJ, Ho IK, Chiou LC.

Int J Neuropsychopharmacol. 2011 Aug;14(7):977-89. doi: 10.1017/S146114571000129X. Epub 2010 Oct 29.

PMID:
21029514
28.

Dimorphic effects of leptin on the circadian and hypocretinergic systems of mice.

Mendoza J, Lopez-Lopez C, Revel FG, Jeanneau K, Delerue F, Prinssen E, Challet E, Moreau JL, Grundschober C.

J Neuroendocrinol. 2011 Jan;23(1):28-38. doi: 10.1111/j.1365-2826.2010.02072.x.

PMID:
20874776
29.

The effects of nociceptin/orphanin FQ receptor agonist Ro 64-6198 and diazepam on antinociception and remifentanil self-administration in rhesus monkeys.

Podlesnik CA, Ko MC, Winger G, Wichmann J, Prinssen EP, Woods JH.

Psychopharmacology (Berl). 2011 Jan;213(1):53-60. doi: 10.1007/s00213-010-2012-7. Epub 2010 Sep 18.

30.

Examining face and construct validity of a noninvasive model of panic disorder in Lister-hooded rats.

Klein S, Nicolas LB, Lopez-Lopez C, Jacobson LH, McArthur SG, Grundschober C, Prinssen EP.

Psychopharmacology (Berl). 2010 Aug;211(2):197-208. doi: 10.1007/s00213-010-1882-z. Epub 2010 Jun 1.

PMID:
20514481
31.

In vitro pharmacological selectivity profile of oseltamivir prodrug (Tamiflu) and active metabolite.

Lindemann L, Jacobsen H, Schuhbauer D, Knoflach F, Gatti S, Wettstein JG, Loetscher H, Chu T, Ebeling M, Paulson JC, Prinssen E, Brockhaus M.

Eur J Pharmacol. 2010 Feb 25;628(1-3):6-10. doi: 10.1016/j.ejphar.2009.11.020. Epub 2009 Nov 14.

32.

Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system.

Hoffmann G, Funk C, Fowler S, Otteneder MB, Breidenbach A, Rayner CR, Chu T, Prinssen EP.

Antimicrob Agents Chemother. 2009 Nov;53(11):4753-61. doi: 10.1128/AAC.01541-08. Epub 2009 Aug 31.

33.

Validating a human model for anxiety using startle potentiated by cue and context: the effects of alprazolam, pregabalin, and diphenhydramine.

Baas JM, Mol N, Kenemans JL, Prinssen EP, Niklson I, Xia-Chen C, Broeyer F, van Gerven J.

Psychopharmacology (Berl). 2009 Jul;205(1):73-84. doi: 10.1007/s00213-009-1516-5. Epub 2009 May 5. Erratum in: Psychopharmacology (Berl). 2010 Jun;210(3):451.

34.

Method development studies for repeatedly measuring anxiolytic drug effects in healthy humans.

Klumpers F, van Gerven JM, Prinssen EP, Niklson I, Roesch F, Riedel WJ, Kenemans JL, Baas JM.

J Psychopharmacol. 2010 May;24(5):657-66. doi: 10.1177/0269881109103115. Epub 2009 Mar 27.

PMID:
19329545
35.

Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys.

Ko MC, Woods JH, Fantegrossi WE, Galuska CM, Wichmann J, Prinssen EP.

Neuropsychopharmacology. 2009 Aug;34(9):2088-96. doi: 10.1038/npp.2009.33. Epub 2009 Mar 11.

36.

Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review.

Toovey S, Rayner C, Prinssen E, Chu T, Donner B, Thakrar B, Dutkowski R, Hoffmann G, Breidenbach A, Lindemann L, Carey E, Boak L, Gieschke R, Sacks S, Solsky J, Small I, Reddy D.

Drug Saf. 2008;31(12):1097-114. doi: 10.2165/0002018-200831120-00006. Review.

PMID:
19026027
37.

RO4938581, a novel cognitive enhancer acting at GABAA alpha5 subunit-containing receptors.

Ballard TM, Knoflach F, Prinssen E, Borroni E, Vivian JA, Basile J, Gasser R, Moreau JL, Wettstein JG, Buettelmann B, Knust H, Thomas AW, Trube G, Hernandez MC.

Psychopharmacology (Berl). 2009 Jan;202(1-3):207-23. doi: 10.1007/s00213-008-1357-7. Epub 2008 Oct 21.

PMID:
18936916
38.

Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers.

Jhee SS, Yen M, Ereshefsky L, Leibowitz M, Schulte M, Kaeser B, Boak L, Patel A, Hoffmann G, Prinssen EP, Rayner CR.

Antimicrob Agents Chemother. 2008 Oct;52(10):3687-93. doi: 10.1128/AAC.00327-08. Epub 2008 Aug 1.

39.

Characterization of (R,S)-5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl-3H-benzofuran-2-one as a positive allosteric modulator of GABAB receptors.

Malherbe P, Masciadri R, Norcross RD, Knoflach F, Kratzeisen C, Zenner MT, Kolb Y, Marcuz A, Huwyler J, Nakagawa T, Porter RH, Thomas AW, Wettstein JG, Sleight AJ, Spooren W, Prinssen EP.

Br J Pharmacol. 2008 Jun;154(4):797-811. doi: 10.1038/bjp.2008.135. Epub 2008 Apr 21.

40.

Metabolite identification via LC-SPE-NMR-MS of the in vitro biooxidation products of a lead mGlu5 allosteric antagonist and impact on the improvement of metabolic stability in the series.

Ceccarelli SM, Schlotterbeck G, Boissin P, Binder M, Buettelmann B, Hanlon S, Jaeschke G, Kolczewski S, Kupfer E, Peters JU, Porter RH, Prinssen EP, Rueher M, Ruf I, Spooren W, Stämpfli A, Vieira E.

ChemMedChem. 2008 Jan;3(1):136-44.

PMID:
17994660
41.

Defensive-like behaviors induced by ultrasound: further pharmacological characterization in Lister-hooded rats.

Nicolas LB, Klein S, Prinssen EP.

Psychopharmacology (Berl). 2007 Oct;194(2):243-52. Epub 2007 Jun 23.

PMID:
17589832
42.

F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.

Depoortère R, Bardin L, Auclair AL, Kleven MS, Prinssen E, Colpaert F, Vacher B, Newman-Tancredi A.

Br J Pharmacol. 2007 May;151(2):253-65. Epub 2007 Mar 20.

43.

Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics.

Bardin L, Auclair A, Kleven MS, Prinssen EP, Koek W, Newman-Tancredi A, Depoortère R.

Behav Pharmacol. 2007 Mar;18(2):103-18.

PMID:
17351418
44.

Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications.

Chiou LC, Liao YY, Fan PC, Kuo PH, Wang CH, Riemer C, Prinssen EP.

Curr Drug Targets. 2007 Jan;8(1):117-35. Review.

PMID:
17266536
45.

Synthesis and biological evaluation of fenobam analogs as mGlu5 receptor antagonists.

Jaeschke G, Porter R, Büttelmann B, Ceccarelli SM, Guba W, Kuhn B, Kolczewski S, Huwyler J, Mutel V, Peters JU, Ballard T, Prinssen E, Vieira E, Wichmann J, Spooren W.

Bioorg Med Chem Lett. 2007 Mar 1;17(5):1307-11. Epub 2006 Dec 15.

PMID:
17196387
46.

Rational design, synthesis, and structure-activity relationship of benzoxazolones: new potent mglu5 receptor antagonists based on the fenobam structure.

Ceccarelli SM, Jaeschke G, Buettelmann B, Huwyler J, Kolczewski S, Peters JU, Prinssen E, Porter R, Spooren W, Vieira E.

Bioorg Med Chem Lett. 2007 Mar 1;17(5):1302-6. Epub 2006 Dec 15.

PMID:
17189691
47.
48.

The effects of serotonin reuptake inhibitors on locomotor activity in gerbils.

Prinssen EP, Ballard TM, Kolb Y, Nicolas LB.

Pharmacol Biochem Behav. 2006 Sep;85(1):44-9. Epub 2006 Aug 22.

PMID:
16920181
49.

Arylmethoxypyridines as novel, potent and orally active mGlu5 receptor antagonists.

Büttelmann B, Peters JU, Ceccarelli S, Kolczewski S, Vieira E, Prinssen EP, Spooren W, Schuler F, Huwyler J, Porter RH, Jaeschke G.

Bioorg Med Chem Lett. 2006 Apr 1;16(7):1892-7. Epub 2006 Jan 24.

PMID:
16439120
50.

Social approach-avoidance behavior of a high-anxiety strain of rats: effects of benzodiazepine receptor ligands.

Nicolas LB, Prinssen EP.

Psychopharmacology (Berl). 2006 Jan;184(1):65-74. Epub 2005 Dec 3.

PMID:
16328377

Supplemental Content

Loading ...
Support Center